Moffitt Cancer Center Administration includes the Research Executive Committee (REX), Scientific Leadership Committee (SLC), and Research Administration. REX establishes the overall scientific direction of the Center through strategic planning investment, evaluation, and nimble, coordinated activities that take advantage of unique opportunities or that address problems. Research Administration operationalizes and supports this vision. REX members include the Center Director and the six Associate Center Directors (ACDs) of Basic, Clinical, Population, and Translational Sciences; Education & Training; and Research Administration. This committee meets weekly for one and a half to two hours. This frequency ensures that activities related to recruitment, research development (including the Grant Review Committee, GRC), planning, space, academic affairs, and policy are rapidly addressed, while fostering a highly collaborative and integrated culture. The REX members are all highly productive scientists and leaders; collectively they have more than 110 years of Cancer Center leadership experience. SLC includes REX plus Program Leaders and Center of Excellence (transdisciplinary interest groups) Leaders. This group advises the Director and REX, with subcommittees for shared resources (Core Leadership Committee, CLC), member evaluation (Membership Committee, MC), clinical science (Clinical Research Action Committee, CRAC), and technology transfer/development (Innovation & Technology Committee, ITC). CCSG Research Administration is composed of 68 (only 2.6 FTE requested) staff members that support Moffitt's 142 Members, 698 other staff, and 13 shared resources. Reporting to the ACD of Research Administration, the administrative unit includes three Senior Directors, five Directors, four Managers, and their teams. Administration assists the Center Director in the ongoing research strategic planning and evaluation process; regular member and staff communications; faculty recruitment; shared resource oversight, including chargebacks, performance review, and user satisfaction; managing the $145 million annual budget, including philanthropic funds; awarding and monitoring more than $2 million in annual institutionally-supported developmental awards; managing and implementing MCC policies for 333,000-sf of dedicated research space; conducting the quarterly membership review and monitoring process; and arranging and documenting approximately 150 Center meetings and retreats per year. The current budget requests for Senior Leadership and Administration are $174,034 (9% of CCSG budget) and $153,888 (8% of CCSG budget), respectively. Collectively this represents less than 0.3% of the overall institutional research budget.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA076292-19
Application #
9209808
Study Section
Subcommittee A - Cancer Centers (NCI-A)
Project Start
Project End
Budget Start
2017-02-01
Budget End
2018-01-31
Support Year
19
Fiscal Year
2017
Total Cost
$460,055
Indirect Cost
$192,581
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
Research Institutes
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Schmit, Stephanie L; Edlund, Christopher K; Schumacher, Fredrick R et al. (2018) Novel Common Genetic Susceptibility Loci for Colorectal Cancer. J Natl Cancer Inst :
Ctortecka, Claudia; Palve, Vinayak; Kuenzi, Brent M et al. (2018) Functional Proteomics and Deep Network Interrogation Reveal a Complex Mechanism of Action of Midostaurin in Lung Cancer Cells. Mol Cell Proteomics 17:2434-2447
Ferreiro-Iglesias, Aida; Lesseur, Corina; McKay, James et al. (2018) Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity. Nat Commun 9:3927
Kang, Sokbom; Thompson, Zachary; McClung, E Claire et al. (2018) Gene Expression Signature-Based Prediction of Lymph Node Metastasis in Patients With Endometrioid Endometrial Cancer. Int J Gynecol Cancer 28:260-266
Kowalski, Allison; Striley, Catherine Woodstock; Varma, Deepthi Satheesa et al. (2018) Interactions between Alcohol Consumption and Adjuvant Hormone Therapy in Relation to Breast Cancer-Free Survival. J Breast Cancer 21:158-164
Konno, Hiroyasu; Yamauchi, Shota; Berglund, Anders et al. (2018) Suppression of STING signaling through epigenetic silencing and missense mutation impedes DNA damage mediated cytokine production. Oncogene 37:2037-2051
Gonzalez, Brian D; Hoogland, Aasha I; Kasting, Monica L et al. (2018) Psychosocial impact of BRCA testing in young Black breast cancer survivors. Psychooncology 27:2778-2785
Akuffo, Afua A; Alontaga, Aileen Y; Metcalf, Rainer et al. (2018) Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon. J Biol Chem 293:6187-6200
Mahajan, Nupam P; Coppola, Domenico; Kim, Jongphil et al. (2018) Blockade of ACK1/TNK2 To Squelch the Survival of Prostate Cancer Stem-like Cells. Sci Rep 8:1954
Rounbehler, Robert J; Berglund, Anders E; Gerke, Travis et al. (2018) Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer. Cancer Epidemiol Biomarkers Prev 27:1376-1383

Showing the most recent 10 out of 1254 publications